Close Menu

Selventa has selected John Tagliamonte to serve as senior vice president of corporate development.

In his new role, Tagliamonte will work on establishing strategic partnerships with global pharmaceutical and biotechnology companies.

Prior to joining Selventa (formerly GenStruct), Tagliamonte was vice president of business development at Anchor Therapeutics and led strategy and corporate development efforts at ImmunoGen. He has also held positions at Millipore, Laureate Pharma, and Johnson & Johnson.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Three US lawmakers call on the Trump Administration to end its program to collect DNA from detained migrants, the Hill reports.

Researchers in the US have developed a promising candidate vaccine against African swine fever, according to Bloomberg News.

Soccer players who head the ball a lot and who have a certain APOE allele may be more likely to have memory problems, according to HealthDay.

In Cell this week: a quantitative proteomic atlas based on the Cancer Cell Line Encyclopedia, gene regulation and differentiation in Toxoplasma gondii, and more.

Feb
20
Sponsored by
Thermo Fisher Scientific

This webinar will discuss the use of 3’ mRNA sequencing to reduce the cost of gene expression studies on Illumina NGS systems.